
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
During a virtual meeting held on April 2nd, EMA’s human medicines committee gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease in compassionate use programs.
To read the reccomendations, click






